Dual targeting of CDK4 and ARK5 using a novel kinase inhibitor ON123300 exerts potent anticancer activity against multiple myeloma

Deepak Perumal, Violetta V. Leshchenko, Pei Yu Kuo, Zewei Jiang, Sai Krishna Athaluri Divakar, Hearn Jay Cho, Ajai Chari, Joshua Brody, M. V.Ramana Reddy, Weijia Zhang, E. Premkumar Reddy, Sundar Jagannath, Samir Parekh

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Multiple myeloma is a fatal plasma cell neoplasm accounting for over 10,000 deaths in the United States each year. Despite new therapies, multiple myeloma remains incurable, and patients ultimately develop drug resistance and succumb to the disease. The response to selective CDK4/6 inhibitors has been modest in multiple myeloma, potentially because of incomplete targeting of other critical myeloma oncogenic kinases. As a substantial number of multiple myeloma cell lines and primary samples were found to express AMPK-related protein kinase 5(ARK5), a member of the AMPK family associated with tumor growth and invasion, we examined whether dual inhibition of CDK4 and ARK5 kinases using ON123300 results in a better therapeutic outcome. Treatment of multiple myeloma cell lines and primary samples with ON123300 in vitro resulted in rapid induction of cell-cycle arrest followed by apoptosis. ON123300-mediated ARK5 inhibition or ARK5-specific siRNAs resulted in the inhibition of the mTOR/S6K pathway and upregulation of the AMPK kinase cascade. AMPK upregulation resulted in increased SIRT1 levels and destabilization of steady-state MYC protein. Furthermore, ON123300 was very effective in inhibiting tumor growth in mouse xenograft assays. In addition, multiple myeloma cells sensitive to ON123300 were found to have a unique genomic signature that can guide the clinical development of ON123300. Our study provides preclinical evidence that ON123300 is unique in simultaneously inhibiting key oncogenic pathways in multiple myeloma and supports further development of ARK5 inhibition as a therapeutic approach in multiple myeloma.

Original languageEnglish (US)
Pages (from-to)1225-1236
Number of pages12
JournalCancer Research
Volume76
Issue number5
DOIs
StatePublished - Mar 1 2016
Externally publishedYes

Fingerprint

AMP-Activated Protein Kinases
Multiple Myeloma
Protein Kinases
Phosphotransferases
Plasma Cell Neoplasms
Up-Regulation
Cell Line
ON123300
Therapeutics
Growth
Cell Cycle Checkpoints
Drug Resistance
Heterografts
Neoplasms
Apoptosis
Inhibition (Psychology)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dual targeting of CDK4 and ARK5 using a novel kinase inhibitor ON123300 exerts potent anticancer activity against multiple myeloma. / Perumal, Deepak; Leshchenko, Violetta V.; Kuo, Pei Yu; Jiang, Zewei; Divakar, Sai Krishna Athaluri; Jay Cho, Hearn; Chari, Ajai; Brody, Joshua; Reddy, M. V.Ramana; Zhang, Weijia; Reddy, E. Premkumar; Jagannath, Sundar; Parekh, Samir.

In: Cancer Research, Vol. 76, No. 5, 01.03.2016, p. 1225-1236.

Research output: Contribution to journalArticle

Perumal, D, Leshchenko, VV, Kuo, PY, Jiang, Z, Divakar, SKA, Jay Cho, H, Chari, A, Brody, J, Reddy, MVR, Zhang, W, Reddy, EP, Jagannath, S & Parekh, S 2016, 'Dual targeting of CDK4 and ARK5 using a novel kinase inhibitor ON123300 exerts potent anticancer activity against multiple myeloma', Cancer Research, vol. 76, no. 5, pp. 1225-1236. https://doi.org/10.1158/0008-5472.CAN-15-2934
Perumal, Deepak ; Leshchenko, Violetta V. ; Kuo, Pei Yu ; Jiang, Zewei ; Divakar, Sai Krishna Athaluri ; Jay Cho, Hearn ; Chari, Ajai ; Brody, Joshua ; Reddy, M. V.Ramana ; Zhang, Weijia ; Reddy, E. Premkumar ; Jagannath, Sundar ; Parekh, Samir. / Dual targeting of CDK4 and ARK5 using a novel kinase inhibitor ON123300 exerts potent anticancer activity against multiple myeloma. In: Cancer Research. 2016 ; Vol. 76, No. 5. pp. 1225-1236.
@article{c544bb9da28e4915889e920780729e0a,
title = "Dual targeting of CDK4 and ARK5 using a novel kinase inhibitor ON123300 exerts potent anticancer activity against multiple myeloma",
abstract = "Multiple myeloma is a fatal plasma cell neoplasm accounting for over 10,000 deaths in the United States each year. Despite new therapies, multiple myeloma remains incurable, and patients ultimately develop drug resistance and succumb to the disease. The response to selective CDK4/6 inhibitors has been modest in multiple myeloma, potentially because of incomplete targeting of other critical myeloma oncogenic kinases. As a substantial number of multiple myeloma cell lines and primary samples were found to express AMPK-related protein kinase 5(ARK5), a member of the AMPK family associated with tumor growth and invasion, we examined whether dual inhibition of CDK4 and ARK5 kinases using ON123300 results in a better therapeutic outcome. Treatment of multiple myeloma cell lines and primary samples with ON123300 in vitro resulted in rapid induction of cell-cycle arrest followed by apoptosis. ON123300-mediated ARK5 inhibition or ARK5-specific siRNAs resulted in the inhibition of the mTOR/S6K pathway and upregulation of the AMPK kinase cascade. AMPK upregulation resulted in increased SIRT1 levels and destabilization of steady-state MYC protein. Furthermore, ON123300 was very effective in inhibiting tumor growth in mouse xenograft assays. In addition, multiple myeloma cells sensitive to ON123300 were found to have a unique genomic signature that can guide the clinical development of ON123300. Our study provides preclinical evidence that ON123300 is unique in simultaneously inhibiting key oncogenic pathways in multiple myeloma and supports further development of ARK5 inhibition as a therapeutic approach in multiple myeloma.",
author = "Deepak Perumal and Leshchenko, {Violetta V.} and Kuo, {Pei Yu} and Zewei Jiang and Divakar, {Sai Krishna Athaluri} and {Jay Cho}, Hearn and Ajai Chari and Joshua Brody and Reddy, {M. V.Ramana} and Weijia Zhang and Reddy, {E. Premkumar} and Sundar Jagannath and Samir Parekh",
year = "2016",
month = "3",
day = "1",
doi = "10.1158/0008-5472.CAN-15-2934",
language = "English (US)",
volume = "76",
pages = "1225--1236",
journal = "Cancer Research",
issn = "0008-5472",
number = "5",

}

TY - JOUR

T1 - Dual targeting of CDK4 and ARK5 using a novel kinase inhibitor ON123300 exerts potent anticancer activity against multiple myeloma

AU - Perumal, Deepak

AU - Leshchenko, Violetta V.

AU - Kuo, Pei Yu

AU - Jiang, Zewei

AU - Divakar, Sai Krishna Athaluri

AU - Jay Cho, Hearn

AU - Chari, Ajai

AU - Brody, Joshua

AU - Reddy, M. V.Ramana

AU - Zhang, Weijia

AU - Reddy, E. Premkumar

AU - Jagannath, Sundar

AU - Parekh, Samir

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Multiple myeloma is a fatal plasma cell neoplasm accounting for over 10,000 deaths in the United States each year. Despite new therapies, multiple myeloma remains incurable, and patients ultimately develop drug resistance and succumb to the disease. The response to selective CDK4/6 inhibitors has been modest in multiple myeloma, potentially because of incomplete targeting of other critical myeloma oncogenic kinases. As a substantial number of multiple myeloma cell lines and primary samples were found to express AMPK-related protein kinase 5(ARK5), a member of the AMPK family associated with tumor growth and invasion, we examined whether dual inhibition of CDK4 and ARK5 kinases using ON123300 results in a better therapeutic outcome. Treatment of multiple myeloma cell lines and primary samples with ON123300 in vitro resulted in rapid induction of cell-cycle arrest followed by apoptosis. ON123300-mediated ARK5 inhibition or ARK5-specific siRNAs resulted in the inhibition of the mTOR/S6K pathway and upregulation of the AMPK kinase cascade. AMPK upregulation resulted in increased SIRT1 levels and destabilization of steady-state MYC protein. Furthermore, ON123300 was very effective in inhibiting tumor growth in mouse xenograft assays. In addition, multiple myeloma cells sensitive to ON123300 were found to have a unique genomic signature that can guide the clinical development of ON123300. Our study provides preclinical evidence that ON123300 is unique in simultaneously inhibiting key oncogenic pathways in multiple myeloma and supports further development of ARK5 inhibition as a therapeutic approach in multiple myeloma.

AB - Multiple myeloma is a fatal plasma cell neoplasm accounting for over 10,000 deaths in the United States each year. Despite new therapies, multiple myeloma remains incurable, and patients ultimately develop drug resistance and succumb to the disease. The response to selective CDK4/6 inhibitors has been modest in multiple myeloma, potentially because of incomplete targeting of other critical myeloma oncogenic kinases. As a substantial number of multiple myeloma cell lines and primary samples were found to express AMPK-related protein kinase 5(ARK5), a member of the AMPK family associated with tumor growth and invasion, we examined whether dual inhibition of CDK4 and ARK5 kinases using ON123300 results in a better therapeutic outcome. Treatment of multiple myeloma cell lines and primary samples with ON123300 in vitro resulted in rapid induction of cell-cycle arrest followed by apoptosis. ON123300-mediated ARK5 inhibition or ARK5-specific siRNAs resulted in the inhibition of the mTOR/S6K pathway and upregulation of the AMPK kinase cascade. AMPK upregulation resulted in increased SIRT1 levels and destabilization of steady-state MYC protein. Furthermore, ON123300 was very effective in inhibiting tumor growth in mouse xenograft assays. In addition, multiple myeloma cells sensitive to ON123300 were found to have a unique genomic signature that can guide the clinical development of ON123300. Our study provides preclinical evidence that ON123300 is unique in simultaneously inhibiting key oncogenic pathways in multiple myeloma and supports further development of ARK5 inhibition as a therapeutic approach in multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=84961736562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961736562&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-2934

DO - 10.1158/0008-5472.CAN-15-2934

M3 - Article

C2 - 26873845

AN - SCOPUS:84961736562

VL - 76

SP - 1225

EP - 1236

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 5

ER -